This isn't the only company to be slowing down now. The cost of short term loans for businesses in the US is absolutely skyrocketing. That and inflation is still very high so the cost of carrying out the trials is now much higher than they first would have expected.@ColinUK, I have to agree. After initial optimism it seems very disappointing. And why would the biotech that paid for the licence sell it back to Hough Ear Institute? You would think they saw no use for it. My guess is Hough Ear Institute have now pulled a random person with tinnitus to proclaim he has been cured to try and offload the pill to another biotech. Really, really poor and a lack of integrity from a non-profit organisation.
Maybe that's not the reason but it's one possible reason.